NVDA Price Target Hikes, STUB Shows No Guidance, MRK Buying CDTX

Group 1: Nvidia - Nvidia is experiencing a mix of pressure and positive sentiment, with analysts expressing confidence in its future performance [1][2] - Wells Fargo raised its price target for Nvidia to $265, anticipating Q3 sales between $50 billion and $52 billion, driven by growing AI demand [2][3] - Morgan Stanley also increased its price target to $220, labeling Nvidia as a core winner in the ongoing AI buildout [3] - Dan Ives from Wed Bush views the current tech pullback as a buying opportunity, asserting that Nvidia is foundational to the AI revolution and expects growth to continue into 2026 [4][5] Group 2: StubHub - StubHub's stock dropped over 20% following disappointing quarterly results and the lack of guidance for the upcoming quarter [6][7] - The company reported a loss exceeding $1.3 billion, with a loss per share of $427, significantly up from $45.9 million the previous year [7][8] - StubHub attributed its losses to a $1.4 billion stock-based compensation charge related to its IPO, but investors reacted negatively [7][8][9] Group 3: Merck - Merck announced a $9.2 billion acquisition of Sedara Therapeutics, leading to a more than 100% increase in Sedara's shares [10][11] - The acquisition aims to provide access to an experimental flu prevention drug, which could serve as a universal protection against various flu strains [10][12] - This move is part of Merck's strategy to diversify its portfolio ahead of the patent expiration of its blockbuster drug, Keytruda [12][13]